Histamine induced high mobility group box-1 release from vascular endothelial cells through H1 receptor

Abstract

BackgroundSystemic allergic reaction is characterized by vasodilation and vascular leakage, which causes a rapid, precipitous and sustained decrease in arterial blood pressure with a concomitant decrease of cardiac output. Histamine is a major mediator released by mast cells in allergic inflammation and response. It causes a cascade of inflammation and strongly increases vascular permeability within minutes through its four G-protein-coupled receptors (GPCRs) on endothelial cells. High mobility group box-1 (HMGB1), a nonhistone chromatin-binding nuclear protein, can be actively secreted into the extracellular space by endothelial cells. HMGB1 has been reported to exert pro-inflammatory effects on endothelial cells and to increase vascular endothelial permeability. However, the relationship between histamine and HMGB1-mediated signaling in vascular endothelial cells and the role of HMGB1 in anaphylactic-induced hypotension have never been studied.Methods and resultsEA.hy 926 cells were treated with different concentrations of histamine for the indicated periods. The results showed that histamine induced HMGB1 translocation and release from the endothelial cells in a concentration- and time-dependent manner. These effects of histamine were concentration-dependently inhibited by d-chlorpheniramine, a specific H1 receptor antagonist, but not by H2 or H3/4 receptor antagonists. Moreover, an H1-specific agonist, 2-pyridylethylamine, mimicked the effects of histamine, whereas an H2-receptor agonist, 4-methylhistamine, did not. Adrenaline and noradrenaline, which are commonly used in the clinical treatment of anaphylactic shock, also inhibited the histamine-induced HMGB1 translocation in endothelial cells. We therefore established a rat model of allergic shock by i.v. injection of compound 48/80, a potent histamine-releasing agent. The plasma HMGB1 levels in compound 48/80-injected rats were higher than those in controls. Moreover, the treatment with anti-HMGB1 antibody successfully facilitated the recovery from compound 48/80-induced hypotension.ConclusionHistamine induces HMGB1 release from vascular endothelial cells solely through H1 receptor stimulation. Anti-HMGB1 therapy may provide a novel treatment for life-threatening systemic anaphylaxis.

Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease

“…Baseline serum fibrinogen levels did not differ between the groups ( Supplemental Figure 1 ). Since histamine acts directly on H1 receptors expressed on ECs ( 15 ), these results suggested an increased functional response to histamine in the ISCLS endothelium.…”

MASTer cell: chief immune modulator and inductor of antimicrobial immune response

“…Circulating cells must traverse blood capillaries to reach the inflammation or infection site without causing damage. This process is facilitated by an increase in vascular permeability mediated by vascular endothelial growth factor via modulation of phosphatidyl inositol 3 kinase–hypoxia-inducible factor-1 ( 66 ) and histamine ( 67 ) released by MCs. The strategic localization of MCs near blood vessels ensures a rapid impact on both blood and lymphatic vessels shortly after MC activation ( 68 ).…”

HMGB1: a double-edged sword and therapeutic target in the female reproductive system

“…HMGB1 is the most mobile protein in the nucleus, and can pass through the nucleus and enter the cytoplasm within 1-2 seconds ( 3 , 29 ). HMGB1 is transferred into the extracellular environment through two different mechanisms: (1) Active secretion: Immune cells and some other cells like epithelial cells and endothelial cells can actively secrete HMGB1 when they are stimulated by various factors ( 30 – 33 ). These factors include lipopolysaccharide (LPS), pathogen infections, and endogenous host stimuli ( 34 , 35 ).…”